SCHEDULE: Samsara BioCapital Cuts Palvella Therapeutics Stake

Samsara BioCapital, L.P. and its affiliates reported a reduced beneficial ownership of 3.1% in Palvella Therapeutics, Inc. common stock as of June 30, 2025.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (collectively, the "Reporting Persons") reported beneficial ownership of Palvella Therapeutics, Inc. common stock.
• As of June 30, 2025, the Reporting Persons collectively beneficially owned 339,743 shares of Palvella Therapeutics, Inc. common stock.
• This ownership represents 3.1% of the total outstanding common stock of Palvella Therapeutics, Inc.
• The percentage is calculated based on 11,055,665 shares of common stock outstanding as of May 9, 2025, as reported by Palvella Therapeutics, Inc. in its Quarterly Report on Form 10-Q filed on May 15, 2025.
• Samsara LP directly holds the 339,743 shares, with Samsara GP and Dr. Akkaraju possessing shared voting and dispositive power.
• The Reporting Persons explicitly disclaim status as a "group" for the purposes of this Schedule 13G.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Palvella Therapeutics, Inc.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in beneficial ownership from above 5% to 3.1%, which can be interpreted as a decrease in investor confidence or a strategic divestment by a significant holder.

Positives

• A notable investment firm, Samsara BioCapital, maintains a significant, albeit reduced, stake in Palvella Therapeutics, Inc., indicating continued, though potentially diminished, interest in the company.

Negatives

• The filing is an Amendment No. 1 and reports a beneficial ownership of 3.1%, which is below the 5% threshold typically requiring an initial Schedule 13G filing, implying a reduction in stake from a previous position that was 5% or greater.

Risks

• The Reporting Persons expressly disclaim status as a "group," which could be a point of regulatory scrutiny if their actions were perceived as coordinated to influence control.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Palvella Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a change in the investment position of Samsara BioCapital, a venture capital firm focused on the life sciences sector, in Palvella Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical industry. Such changes in significant investor stakes are closely watched within the industry as they can signal shifts in investor confidence or strategic portfolio adjustments.

Comparison to Industry Standards

• This is a standard Schedule 13G amendment filing, indicating a passive investment position that has fallen below the 5% threshold. There are no specific comparable companies, projects, or results mentioned within this filing to assess against industry benchmarks.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by Samsara BioCapital as a negative signal regarding the company's prospects or the investor's long-term commitment, potentially leading to a decrease in share price.
• Potential investors might view this reduction as a cautionary sign, influencing their investment decisions.

Next Steps

• No specific future actions or milestones are mentioned by the reporting persons in this filing.

Key Dates

Recommendation

The filing indicates that a significant investor, Samsara BioCapital, has reduced its stake in Palvella Therapeutics, Inc. to 3.1%, implying a divestment from a previous position above 5%. While not a complete exit, this reduction suggests a potential decrease in conviction or a portfolio rebalancing. For a seasoned investor, this signals caution, warranting a 'hold' recommendation to observe further developments rather than a 'buy' or 'sell' based solely on this ownership change, as the underlying reasons for the reduction are not disclosed.

Keywords

Palvella Therapeutics, Samsara BioCapital, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Pharmaceutical, Investment Firm